23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae

Controversy exists regarding the clinical effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the prevention of serotype-specific community-acquired pneumonia (CAP). The objective of this study was to define the effectiveness of PPSV23 for the prevention of CAP hospitaliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandler, Thomas, Furmanek, Stephen, Carrico, Ruth, Balcom, Dawn, Arnold, Forest, Ramirez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951401/
https://www.ncbi.nlm.nih.gov/pubmed/35336135
http://dx.doi.org/10.3390/microorganisms10030560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951401/
https://www.ncbi.nlm.nih.gov/pubmed/35336135
http://dx.doi.org/10.3390/microorganisms10030560

Ejemplares similares